SCHEMBL532890

SCHEMBL532890

CS(=O)(=O)NCc1cccc(-c2nn3cc(I)nc3s2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.46
CHUK O15111 1/20 0.46
BRD4 O60885 1/20 0.44
CA12 O43570 7/20 0.41
CA1 P00915 7/20 0.41
CA2 P00918 7/20 0.41
CA9 Q16790 7/20 0.41
TP53 P04637 1/20 0.41
LIPG Q9Y5X9 1/20 0.38
CYP2D6 P10635 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
AAK1 Q2M2I8 1/20 0.38
AURKA O14965 2/20 0.37
AURKB Q96GD4 2/20 0.37
CSNK1D P48730 1/20 0.37
CSNK1E P49674 1/20 0.37
CPT2 P23786 1/20 0.37
CPT1A P50416 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL532646 0.80 CA12 (0.45) CA12CA1CA2CA9TP53
SCHEMBL532868 0.79 BRD4 (0.47) IKBKBCHUKBRD4LIPGAAK1
SCHEMBL532669 0.77 PIK3CA (0.54) IKBKBCHUKCA12CA1CA2
SCHEMBL2253625 0.75 TP53 (0.69) CA12CA1CA2CA9TP53
SCHEMBL533516 0.71 PDE4D (0.47) CA12CA1CA2CA9TP53
SCHEMBL532982 0.69 MAPK1 (0.58) BRD4
SCHEMBL532668 0.67 PIK3CA (0.74) IKBKBCHUKBRD4CSNK1DCSNK1E
SCHEMBL532199 0.66 ALDH1A1 (0.61) CA12CA1CA2CA9
SCHEMBL3102964 0.66 CYP19A1 (0.49) BRD4CA12CA2
SCHEMBL15975839 0.66 PIK3CA (0.66) IKBKBCHUKBRD4CSNK1DCSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414369-B1 IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) 2015-08-12 EP disclosed
US-8815918-B2 Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2014-08-26 US disclosed
US-20120094996-A1 Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2012-04-19 US disclosed
EP-2414369-A1 IMIDAZO [2, 1-B][ 1, 3, 4]THIADIAZOLE DERIVATIVES Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2012-02-08 EP disclosed
WO-2010112874-A1 IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2010-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094996-A1 Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives PIK3CA, PI4KA, PIK3CD IKBKB 536/4885CHUK 261/4885BRD4 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.